USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin base filmtab tablets and other antibacterial drugs, erythromycin base filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin base filmtab tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible

USA - engelsk - NLM (National Library of Medicine)

stat rx usa llc - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin base filmtab tablets and other antibacterial drugs, erythromycin base filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin base filmtab tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible

USA - engelsk - NLM (National Library of Medicine)

stat rx usa - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin delayed-release capsules and other antibacterial drugs, erythromycin delayed-release capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the er

USA - engelsk - NLM (National Library of Medicine)

rebel distributors corp - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin base filmtab tablets and other antibacterial drugs, erythromycin base filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin base filmtab tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the ery

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - erythromycin ethylsuccinate 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susce

USA - engelsk - NLM (National Library of Medicine)

wilshire pharmaceuticals inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - erythromycin 200 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenza e are not susceptible to the erythromycin concentrati

USA - engelsk - NLM (National Library of Medicine)

arbor pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, usp and other antibacterial drugs, erythromycin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin tablets, usp are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations

USA - engelsk - NLM (National Library of Medicine)

mayne pharma inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes, streptococcus pneumoniae, or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pneumoniae or streptococcus pyogenes. listeriosis caused by listeria monocytogenes. pertussis (whooping cough) caused by bordetella pertussis. erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible indivi

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, usp and other antibacterial drugs, erythromycin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin tablets, usp are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae ar

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, usp and other antibacterial drugs, erythromycin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin tablets, usp are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae ar